These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 4463167)

  • 21. Protective effect of different mouse interferons in mice infected with encephalomyocarditis (EMC).
    Lobodzińska M; Albin M
    Arch Immunol Ther Exp (Warsz); 1982; 30(1-2):49-55. PubMed ID: 6184029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of mice with macrophage colony stimulating factor (CSF-1) prevents the in vivo myelosuppression induced by murine alpha, beta, and gamma interferons.
    Koren S; Klimpel GR; Fleischmann WR
    J Biol Response Mod; 1986 Oct; 5(5):481-9. PubMed ID: 3095498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic effects of orally administered interferons and interleukin-2.
    Fleischmann WR; Koren S
    J Interferon Cytokine Res; 1999 Aug; 19(8):829-39. PubMed ID: 10476926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measurement of effects of human leukocyte interferon on human granulocyte colony-forming cells in vitro.
    Verma DS; Spitzer G; Gutterman JU
    Methods Enzymol; 1981; 79(Pt B):520-6. PubMed ID: 6173704
    [No Abstract]   [Full Text] [Related]  

  • 25. Administration of interferon-alpha in mice provokes peripheral and central modulation of immune cells, accompanied by behavioral effects.
    Orsal AS; Blois SM; Bermpohl D; Schaefer M; Coquery N
    Neuropsychobiology; 2008; 58(3-4):211-22. PubMed ID: 19212136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two methods for the removal of erythrocytes from buffy coats for the production of human leukocyte interferon.
    van Oss CJ; Bronson PM; Dinolfo EA; Chadha KC
    Immunol Commun; 1981; 10(6):549-55. PubMed ID: 6172368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ganoderma lucidum polysaccharides enhance the function of immunological effector cells in immunosuppressed mice.
    Zhu XL; Chen AF; Lin ZB
    J Ethnopharmacol; 2007 May; 111(2):219-26. PubMed ID: 17182202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Inhibitor of the action of swine leukocyte interferon].
    Parfenov VV; Timofeev IV; Zubanova NA
    Vopr Virusol; 1982; 27(3):338-41. PubMed ID: 6181615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon and spontaneous cytotoxicity in man. IV. Evidence for interferon as the factor in human interferon preparations causing enhancement of spontaneous cytotoxicity.
    Einhorn S
    J Clin Lab Immunol; 1980 Jan; 3(1):35-8. PubMed ID: 6155470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of exogenous interferon: acceleration of autoimmune and renal diseases in (NZB/W) F1 mice.
    Adam C; Thoua Y; Ronco P; Verroust P; Tovey M; Morel-Maroger L
    Clin Exp Immunol; 1980 May; 40(2):373-82. PubMed ID: 6160000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The interferon-induced and antiviral activities of dipeptides].
    Nosik NN; Lavrukhina LA; Kondrashina NG; Garaev TM; Shibnev VA
    Vopr Virusol; 2010; 55(3):41-3. PubMed ID: 20608081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Species specificity study of swine leukocyte interferon on different cell cultures].
    Pokidysheva LN; Lavrukhina LA
    Vopr Virusol; 1980; (6):676-8. PubMed ID: 6164162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circadian variations in myelosuppressive activity of interferon-alpha in mice: identification of an optimal treatment time associated with reduced myelosuppressive activity.
    Koren S; Fleischmann WR
    Exp Hematol; 1993 Apr; 21(4):552-9. PubMed ID: 8462664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physico-chemical properties of interferon produced by a mixed leukocyte suspension.
    Táborský I; Dolník V
    Acta Virol; 1977 Sep; 21(5):359-64. PubMed ID: 22229
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of taurine on leucocyte function.
    Wang L; Zhao N; Zhang F; Yue W; Liang M
    Eur J Pharmacol; 2009 Aug; 616(1-3):275-80. PubMed ID: 19490912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes.
    Lindahl P; Leary P; Gresser I
    Proc Natl Acad Sci U S A; 1972 Mar; 69(3):721-5. PubMed ID: 4501586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparative assessment of the properties of a factor inhibiting macrophage migration and interferon].
    Mel'nikov OF; Krivokhatskaia LD; Povolotskiĭ IaL
    Biull Eksp Biol Med; 1977 Mar; 83(3):302-3. PubMed ID: 322762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The immunomodulating action of interferon preparations. 3. Changes in the phagocytic activity of human blood neutrophilic granulocytes under the influence of interferon preparations].
    Avdeeva ZhI; Mazina NM; Vakhromeeva NS; Krylov OP; Moskalenko MB; Medunitsyn NV
    Vestn Dermatol Venerol; 1990; (8):23-8. PubMed ID: 1701593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of polyinosinic: polycytidylic acid on the circulating white blood cells in mice.
    Degré M
    Proc Soc Exp Biol Med; 1973 Apr; 142(4):1087-91. PubMed ID: 4694806
    [No Abstract]   [Full Text] [Related]  

  • 40. Two mechanisms of interferon production by leukocytes from immunized animals.
    Trubina LM; Yakovenko ZF; Zakharchenko EM; Lychkovskaya EV
    Acta Virol; 1975 Apr; 19(2):116-20. PubMed ID: 239556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.